Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Syngene International IPO is a book build issue of ₹550.00 crores. The issue is entirely an offer for sale of 2.20 crore shares of ₹550.00 crore.
Syngene International IPO bidding started from Jul 27, 2015 and ended on Jul 29, 2015. The shares got listed on BSE, NSE on Aug 11, 2015.
Syngene International IPO price band is set at ₹250.00 per share . The lot size for an application is 60. The minimum amount of investment required by an retail is ₹14,400 (60 shares). The lot size investment for sNII is 14 lots (840 shares), amounting to ₹2,10,000, and for bNII, it is 67 lots (4,020 shares), amounting to ₹10,05,000.
Axis Bank Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
Refer to Syngene International IPO RHP for detailed Information.
| IPO Date | July 27, 2015 to July 29, 2015 |
| Listing Date | August 11, 2015 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹240 to ₹250 per share |
| Issue Price Final | ₹250 per share |
| Lot Size | 60 Shares |
| Sale Type | Offer For Sale |
| Total Issue Size | 2,20,00,000 shares (aggregating up to ₹550.00 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 20,00,00,000 shares |
| Share Holding Post Issue | 20,00,00,000 shares |
Syngene International IPO offers total 2,20,00,000 shares. Out of which 1,00,00,000 (45.45%) allocated to QIB, 40,00,000 (18.18%) allocated to QIB, 30,00,000 (13.64%) allocated to NII, 70,00,000 (31.82%) allocated to RII and 60,00,000 (27.27%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 1,00,00,000 (45.45%) | NA |
| − Anchor Investor Shares Offered | 60,00,000 (27.27%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 40,00,000 (18.18%) | NA |
| NII (HNI) Shares Offered | 30,00,000 (13.64%) | NA |
| Retail Shares Offered | 70,00,000 (31.82%) | 1,16,666 |
| Shareholders Shares Offered | 20,00,000 (9.09%) | NA |
| Total Shares Offered | 2,20,00,000 (100.00%) |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only shareholder | Up to Rs 2 Lakhs | Yes |
| Shareholder + RII/NII |
|
Yes for shareholder/RII |
Note: To be eligible for the Shareholder Quota, you must hold shares in one of the following companies:
Syngene International IPO opens on July 27, 2015, and closes on July 29, 2015.
| IPO Open Date | Mon, Jul 27, 2015 |
| IPO Close Date | Wed, Jul 29, 2015 |
| Tentative Listing Date | Tue, Aug 11, 2015 |
| Cut-off time for UPI mandate confirmation | 5 PM on Wed, Jul 29, 2015 |
Investors can bid for a minimum of 60 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 60 | ₹15,000 |
| Retail (Max) | 13 | 780 | ₹1,95,000 |
| S-HNI (Min) | 14 | 840 | ₹2,10,000 |
| S-HNI (Max) | 66 | 3,960 | ₹9,90,000 |
| B-HNI (Min) | 67 | 4,020 | ₹10,05,000 |
Incorporated in 1993, Syngene International Ltd is a subsidiary of Biocon Limited ("Biocon"), a global biopharmaceutical enterprise focused on delivering affordable formulations and compounds.
Headquartered in Bengaluru, Syngene International is India-based contract research organisations ("CRO"), offering a suite of integrated, end-to-end discovery and development services for novel molecular entities ("NMEs") across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. Their services in discovery and development cover multiple domains across small molecules, large molecules, antibody-drug conjugates ("ADC") and oligonucleotides.
Syngene offer customized models as per their clients requirements. These range from a full-time equivalent ("FTE") to a fee-for-service ("FFS") model, or a combination thereof. Till Dec 31, 2014, they serviced 195 clients, ranging from multinational corporations to start-ups, including seven of the top 10 global pharmaceutical companies by sales for 2014. Company's long term clients includes global healthcare organisations Bristol-Myers Squibb Co. ("BMS"), Abbott Laboratories (Singapore) Pte. Ltd. ("Abbott") and Baxter International Inc. ("Baxter").
| Particulars | For the year/period ended (in Rs. Million) | |||
| 31 Dec 14 | 31 Mar 14 | 31 Mar 13 | 31 Mar 12 | |
| Total Income | 6,175 | 7,077 | 5,542 | 4,182 |
| Profit After Tax (PAT) | 1,194 | 1,348 | 1,021 | 710 |
The Company Syngene International IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | To Meet Working Capital Requirement | 28.40 |
| 2 | Public Issue Expenses | 4.00 |
[Dilip Davda] <p><strong>Syngene Intl Ltd - Modest investment recommended</strong></p> <p><em>DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published here. Any reader taking decisions based on any information published here does so entirely at own risk. Author has no plans to invest in this offer.</em></p> Read detail review...
| Listing Date | August 11, 2015 |
| BSE Script Code | 539268 |
| NSE Symbol | SYNGENE |
| ISIN | INE398R01022 |
| Final Issue Price | ₹250 per share |
| BSE Listing Group | B |
Syngene International Ltd.
Biocon SEZ Biocon Park,
Plot No 2 & 3 Bommasandra Inds,
Bengaluru - 560099, Karnataka
Bengaluru, Karnataka
Phone: +91-80-28082808
Email: investor@syngeneintl.com
Website: http://www.syngeneintl.com
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: einward.ris@karvy.com
Website: https://ipostatus.kfintech.com/
Syngene International IPO is a main-board IPO of 2,20,00,000 equity shares of the face value of ₹10 aggregating up to ₹550.00 Crores. The issue is priced at ₹250 per share. The minimum order quantity is 60.
The IPO opens on July 27, 2015, and closes on July 29, 2015.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Syngene International IPO using UPI as a payment gateway. Zerodha customers can apply in Syngene International IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Syngene International IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Syngene International IPO opens on July 27, 2015 and closes on July 29, 2015.
Syngene International IPO lot size is 60, and the minimum amount required for application is ₹15,000.
You can apply in Syngene International IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Syngene International IPO will be done on [.], and the allotted shares will be credited to your demat account by [.]. Check the Syngene International IPO allotment status.
The Syngene International IPO listing date is on Tuesday, August 11, 2015.
Useful Articles
RHP